Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Gerald S. Falchook | Researchclopedia

Back to researchers

Gerald S. Falchook

Sarah Cannon Research Institute ORCID

808

Works

26,697

Citations

68

h-index

225

i10-index

Research Topics

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies Cancer Genomics and Diagnostics

Affiliations

Biogen (United States)2013–2013

Memorial Sloan Kettering Cancer Center2019–2022

The University of Texas MD Anderson Cancer Center2006–2023

Institute of Cancer Research2017–2017

University of Miami2019–2019

Top Works

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty,J. Infante,et al.

20122,786 citations

Cancer Immunotherapy and Biomarkers

PI3K/AKT/mTOR signaling in cancer

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon,Karen Rex,et al.

20192,189 citations

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Ferdinandos Skoulidis,Bob T. Li,et al.

20211,688 citations

KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong,Marwan Fakih,et al.

20201,647 citations

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook,Georgina V. Long,et al.

2012929 citations

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

David S. Hong,Yoon‐Koo Kang,et al.

2020867 citations

Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

Alexander Drilon,Geoffrey R. Oxnard,et al.

2020819 citations

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante,Leslie A. Fecher,et al.

2012554 citations

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

Gerald S. Falchook,Karl D. Lewis,et al.

2012539 citations